Receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors have been reported in a Shanghai Institute of Organic Chemistry patent as potentially useful for the treatment of cancer, atopic dermatitis, psoriasis, macular degeneration, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel and Alzheimer’s disease, among others.